ライフサイエンスコーパス: aldosterone synthase

1 xycorticosterone, the immediate substrate of aldosterone synthase.

2 dogenesis factor-1-dependent upregulation of aldosterone synthase.

3 yme that shares 93% sequence similarity with aldosterone synthase.

4 The -344C allele, associated with higher aldosterone synthase activity, has been linked to hypert

5 hesis involves three membrane-bound enzymes: aldosterone synthase, adrenodoxin, and adrenodoxin reduc

6 g classes, eg, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agon

7 ), but the adjacent candidate genes Cyp11b2 (aldosterone synthase) and Cyp11b3 were ruled out.

8 utations (compared to wildtype) was CYP11B2 (aldosterone synthase), and biological rhythms were the m

9 CYP11B2, the aldosterone synthase, and CYP11B1, the cortisol synthase

10 Aldosterone synthase (AS) regulates blood volume by synt

11 Aldosterone synthase (AS, cytochrome P450 11B2, cyp11B2)

12 d overexpression of P450 11B2 (also known as aldosterone synthase) can lead to hypertension, congesti

13 inoma cell line (H295R) overexpressing human aldosterone synthase cDNA was established.

14 ts to quantify the selectivity of LCI699 for aldosterone synthase compared with 11-beta-hydroxylase.

15 ing enzyme and steroid 11 beta-monooxygenase/aldosterone synthase complex depending on the steroidoge

16 Aldosterone synthase controls the synthesis of aldostero

17 hat the C-allele containing genotypes of the aldosterone synthase CYP11B2 T(-344)C gene polymorphism

18 Dual inhibitors of aromatase (CYP19) and aldosterone synthase (CYP11B2) are therefore proposed as

19 he adipokine leptin is a direct regulator of aldosterone synthase (CYP11B2) expression and aldosteron

20 The relationship between age and adrenal aldosterone synthase (CYP11B2) expression was evaluated

21 al studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising

22 Aldosterone synthase (CYP11B2) inhibitors have been expl

23 In PA, hypomethylation of aldosterone synthase (CYP11B2) is associated with aldost

24 The enzyme aldosterone synthase (CYP11B2) is responsible for the fi

25 The inhibition of aldosterone synthase (CYP11B2) to reduce aldosterone lev

26 in rat telemetry studies and no increase of aldosterone synthase (CYP11B2) was detected in H295R cel

27 ell clusters (APCCs) with high expression of aldosterone synthase (CYP11B2) were found in both normal

28 nhibitors proved to be able to interact with aldosterone synthase (CYP11B2), a cytochrome P450 enzyme

29 angiotensin II type 1 receptor (AGTR1), and aldosterone synthase (CYP11B2), including sex-SNP or SNP

30 d by dysregulated localization of the enzyme aldosterone synthase (Cyp11b2), which is normally restri

31 Therefore, the inhibition of aldosterone synthase (CYP11B2), which is the pivotal enz

32 protein 1), as well as the gene encoding an aldosterone synthase (Cyp11b2).

33 Aldosterone synthase deficiency, salt-wasting forms of c

34 tochrome P-450 steroid 11 beta-monooxygenase/aldosterone synthase, EC 1.14.15.4).

35 twofold, including a three-fold increase in aldosterone synthase expression in adrenal gland, and a

36 J5MUT-induced induction of CYP11B2 (encoding aldosterone synthase) expression and aldosterone product

37 Their adrenal Cyp11b2 (aldosterone synthase) expression was increased and remai

38 orphism exists in the promoter region of the aldosterone synthase gene (CYP11B2) at position -344 (T/

39 e polymorphism (SNP) at position -344 of the aldosterone synthase gene (CYP11B2).

40 tween single-nucleotide polymorphisms in the aldosterone synthase gene and plasma glucose levels in a

41 his study was to examine the extent to which aldosterone synthase genotype (CYP11B2) and genetic ance

42 the effects of increased expression of human aldosterone synthase (hAS) on blood pressure (BP), we es

43 size a fluorine-18 labeled, highly selective aldosterone synthase (hCYP11B2) inhibitor, [(18)F]AldoVi

44 pport additional research to evaluate use of aldosterone synthase inhibition in primary hypertension

45 Aldosterone synthase inhibition with LCI699 significantl

46 lin receptor type A blockade in ZENITH-CKD), aldosterone synthase inhibition, and targeted anti-infla

47 r losartan and by spironolactone, but not by aldosterone synthase inhibition.

48 Lorundrostat, a novel aldosterone synthase inhibitor that reduces aldosterone

49 Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy

50 hase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy, safety, an

51 The efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, was demonstrated for low

52 owering in broad groups of patients, such as aldosterone synthase inhibitors and dual endothelin rece

53 eroidal MRA, partial agonists of the MR, and aldosterone synthase inhibitors in cardio-kidney disease

54 ating aldosterone production using selective aldosterone synthase inhibitors is an emerging approach

55 Additionally, aldosterone synthase inhibitors may emerge as a therapeu

56 We now report novel series of aldosterone synthase inhibitors with single-digit nanomo

57 C to T conversion at position -344) encoding aldosterone synthase is associated with hypertension, pa

58 Selective inhibition of aldosterone synthase is essential but difficult to achie

59 eases, dual inhibition of CYP19 and CYP11B2 (aldosterone synthase) is a promising treatment for breas

60 ochrome P450 side chain cleavage enzyme) and aldosterone synthase, it did inhibit 3betaHSD2 expressio

61 We studied aldosterone synthase knockout (AS(-/-)) mice to define r

62 ents of Aldosterone signaling, including the Aldosterone-Synthase KO (AS-KO) and the Mineralocorticoi

63 We show myocardial aldosterone and aldosterone synthase mRNA levels were elevated by 4- to

64 eart Failure Trial demonstrate the impact of aldosterone synthase polymorphism on left ventricle remo

65 ericans) substudy and were genotyped for the aldosterone synthase polymorphism.

66 The aldosterone synthase promoter -344C allele linked to hig

67 We sought to evaluate the effect of the aldosterone synthase promoter polymorphism on heart fail

68 Aldosterone synthase protein levels are increased in leu

69 LCI699, a novel inhibitor of aldosterone synthase, reduces serum aldosterone, and may

70 ldosterone by cytochrome P450 11B2 (CYP11B2, aldosterone synthase) requires two reduction events with

71 subfamily B member 2 (hCYP11B2) gene encodes aldosterone synthase, the rate-limiting enzyme in the bi

72 Fadrozole (an inhibitor of aldosterone synthase) treatment significantly reduced BP